Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases.

Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL.

J Med Imaging Radiat Oncol. 2013 Feb;57(1):72-80. doi: 10.1111/j.1754-9485.2012.02459.x. Epub 2012 Oct 9.

PMID:
23374558
2.

Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.

Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL.

J Vasc Interv Radiol. 2012 Jan;23(1):96-105. doi: 10.1016/j.jvir.2011.09.028. Epub 2011 Nov 12.

PMID:
22079516
3.

Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.

Benson AB 3rd, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R.

Eur J Cancer. 2013 Oct;49(15):3122-30. doi: 10.1016/j.ejca.2013.05.012. Epub 2013 Jun 15.

PMID:
23777743
4.

Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases.

Cianni R, Urigo C, Notarianni E, Saltarelli A, D'Agostini A, Iozzino M, Dornbusch T, Cortesi E.

Radiol Med. 2010 Jun;115(4):619-33. doi: 10.1007/s11547-010-0496-1. Epub 2010 Jan 20. English, Italian.

PMID:
20091135
5.

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.

Abdel-Rahman OM, Elsayed Z.

Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Review.

PMID:
26905230
6.

Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres.

Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L.

J Vasc Interv Radiol. 2010 Oct;21(10):1521-6. doi: 10.1016/j.jvir.2010.06.018. Epub 2010 Sep 1.

PMID:
20813542
7.

Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.

Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA.

Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464.

PMID:
22920685
8.

Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy.

Golfieri R, Mosconi C, Giampalma E, Cappelli A, Galaverni MC, Pettinato C, Renzulli M, Monari F, Mazzarotto R, Pinto C, Angelelli B.

Radiol Med. 2015 Aug;120(8):767-76. doi: 10.1007/s11547-015-0504-6. Epub 2015 Feb 13.

PMID:
25678128
9.

Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases.

Smits ML, van den Hoven AF, Rosenbaum CE, Zonnenberg BA, Lam MG, Nijsen JF, Koopman M, van den Bosch MA.

PLoS One. 2013 Jul 24;8(7):e69448. doi: 10.1371/journal.pone.0069448. Print 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/559e04cc-b09c-4b5c-9405-56837f6d5627.

10.

Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.

Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA, Tzou KS, Paz-Fumagalli R, Kim S, Ko SJ, Daugherty LC, Kim GP, Brown N, Mori KW, Buskirk SJ.

Brachytherapy. 2013 Nov-Dec;12(6):573-9. doi: 10.1016/j.brachy.2013.05.008. Epub 2013 Aug 14.

PMID:
23953810
11.

Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.

Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Helmberger TK, Reiser MF.

J Vasc Interv Radiol. 2008 Aug;19(8):1187-95. doi: 10.1016/j.jvir.2008.05.013. Epub 2008 Jun 27.

PMID:
18656012
12.

Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors.

Bester L, Feitelson S, Milner B, Chua TC, Morris DL.

Am J Clin Oncol. 2014 Oct;37(5):454-60. doi: 10.1097/COC.0b013e31827deea1.

PMID:
23388564
13.

Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.

Klingenstein A, Haug AR, Zech CJ, Schaller UC.

Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65. doi: 10.1007/s00270-012-0373-5. Epub 2012 Apr 21.

PMID:
22526099
14.

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R.

Am J Clin Oncol. 2008 Jun;31(3):271-9. doi: 10.1097/COC.0b013e31815e4557.

PMID:
18525307
15.

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO).

Br J Cancer. 2010 Jul 27;103(3):324-31. doi: 10.1038/sj.bjc.6605770. Epub 2010 Jul 13.

16.

Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.

Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V.

Oncology. 2014;86(1):24-32. doi: 10.1159/000355821. Epub 2013 Dec 21.

PMID:
24401529
17.

Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.

Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV.

J Vasc Interv Radiol. 2011 Dec;22(12):1697-705. doi: 10.1016/j.jvir.2011.08.013. Epub 2011 Oct 8.

PMID:
21983055
18.

Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography.

Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Bar-Ad V, Dicker A, Doyle L, Li J, Sato T.

Am J Clin Oncol. 2016 Apr;39(2):189-95. doi: 10.1097/COC.0000000000000033.

19.

Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.

Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF.

Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42. doi: 10.1007/s00270-011-0248-1. Epub 2011 Aug 17.

PMID:
21847708
20.

Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer.

Cianni R, Pelle G, Notarianni E, Saltarelli A, Rabuffi P, Bagni O, Filippi L, Cortesi E.

Eur Radiol. 2013 Jan;23(1):182-9. doi: 10.1007/s00330-012-2556-5. Epub 2012 Jul 27.

PMID:
22836160

Supplemental Content

Support Center